{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:02:30Z","timestamp":1790427750935,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bneo.2026.100292","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:30:36Z","timestamp":1787675436000},"page":"100292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CPX-351 plus gemtuzumab ozogamicin in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-7937","authenticated-orcid":false,"given":"Yesid","family":"Alvarado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-2567","authenticated-orcid":false,"given":"Jayastu","family":"Senapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-4196","authenticated-orcid":false,"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-8485","authenticated-orcid":false,"given":"Fadi G.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Bataller","family":"Torralba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8162-4119","authenticated-orcid":false,"given":"Sankalp","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bneo.2026.100292_bib1","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.3324\/haematol.2024.285057","article-title":"Outcomes and genetic dynamics of acute myeloid leukemia at first relapse","volume":"109","author":"Bataller","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bneo.2026.100292_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35806","article-title":"Therapeutic horizon of acute myeloid leukemia: success, optimism, and challenges","volume":"131","author":"Senapati","year":"2025","journal-title":"Cancer"},{"issue":"26","key":"10.1016\/j.bneo.2026.100292_bib3","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100292_bib4","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100292_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bneo.2026.100292_bib6","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/ajh.26700","volume":"97","author":"Borthakur","year":"2022","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100292_bib7","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1200\/JCO.23.00943","article-title":"Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed AML and overall survival in patients with NPM1 and FLT3 Mutations","volume":"42","author":"Russell","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100292_bib8","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood.2025031006","article-title":"CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non\u2013adverse-risk AML: the NCRI AML18 trial","volume":"147","author":"Knapper","year":"2026","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bneo.2026.100292_bib9","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.bneo.2026.100292_bib10","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bneo.2026.100292_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.bneo.2026.100292_bib12","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO-25-01694","article-title":"Ziftomenib in relapsed or refractory NPM1-mutated AML","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100292_bib13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-025-01751-w","article-title":"Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort","volume":"18","author":"Cortes","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100292_bib14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA approval summary: mylotarg for treatment of patients with relapsed or Refractory CD33-positive acute myeloid leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100292_bib15","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2025-2075","article-title":"Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes","volume":"146","author":"Chien","year":"2025","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.bneo.2026.100292_bib16","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100292_bib17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100292_bib18","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody\u2013drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100292_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bict.2025.100030","article-title":"CAR-NK cell therapy in acute myeloid leukemia: safer, smarter, and moving toward clinical translation","volume":"2","author":"Drayton","year":"2026","journal-title":"Blood Immunol Cell Ther"},{"issue":"8","key":"10.1016\/j.bneo.2026.100292_bib20","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/ajh.27723","article-title":"A phase 2 trial of CPX-351 combined with venetoclax in relapsed or refractory acute myeloid leukemia","volume":"100","author":"Kadia","year":"2025","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100292_bib21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ajh.27561","article-title":"Outcomes of patients with treated secondary acute myeloid leukemia: a high-risk subtype that warrants an independent prognostic designation","volume":"100","author":"Senapati","year":"2025","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100292_bib22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/10428194.2024.2438809","article-title":"CPX-351 plus gemtuzumab ozogamicin for relapsed\/refractory acute myelogenous leukemia: a University of California hematologic malignancies consortium trial","volume":"66","author":"Oliai","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100292_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-139494","article-title":"A phase I\/II trial of CPX-351 + palbociclib in patients with acute myeloid leukemia","volume":"136","author":"Nazha","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100292_bib24","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1182\/blood-2023-186671","article-title":"A two-part study evaluating the combination of tazemetostat and CPX-351 (Part 1) and palbociclib with CPX-351 (part 2) for the treatment of relapsed or refractory acute myeloid leukemia","volume":"142","author":"Keiffer","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2026.100292_bib25","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.bneo.2026.100292_bib26","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/bloodadvances.2025019378","article-title":"CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial","volume":"10","author":"Shimony","year":"2026","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.bneo.2026.100292_bib27","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial","volume":"7","author":"Othman","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.bneo.2026.100292_bib28","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1182\/bloodadvances.2019001278","article-title":"A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)","volume":"4","author":"Lancet","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2026.100292_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35662","article-title":"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia","volume":"131","author":"Jen","year":"2025","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bneo.2026.100292_bib30","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1158\/2643-3230.BCD-25-0477","article-title":"Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trial","volume":"7","author":"Senapati","year":"2026","journal-title":"Blood Cancer Discov"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026001032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026001032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:51:43Z","timestamp":1790427103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026001032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2950328026001032"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100292","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CPX-351 plus gemtuzumab ozogamicin in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100292"}}